Published online before print July 19, 2004, doi: 10.1161/01.CIR.0000136821.99814.43
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;110:508-514.)
© 2004 American Heart Association, Inc.
Original Articles |
Cost-Effectiveness of Sirolimus-Eluting Stents for Treatment of Complex Coronary Stenoses
Results From the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) Trial
From the Harvard Clinical Research Institute, Boston, Mass (D.J.C., A.B., C.S., L.G., T.L., R.H.B., R.E.K.); Division of Cardiology, Beth Israel-Deaconess Medical Center, Boston, Mass (D.J.C., A.B., J.P.C.); Clinical Trials and Evaluation Unit, Royal Brompton Hospital, London, UK (A.B.); Lenox Hill Hospital, New York, NY (M.B.L., J.W.M.); and Duke University Medical Center, Durham, NC (J.P.Z.).
Correspondence to David J. Cohen, MD, Cardiovascular Division, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215. E-mail dcohen{at}caregroup.harvard.edu
Received January 4, 2004; revision received April 20, 2004; accepted April 22, 2004.
Background— Recently, sirolimus-eluting stents (SESs) have been shown to dramatically reduce the risk of angiographic and clinical restenosis compared with bare metal stent (BMS) implantation. However, the overall cost-effectiveness of this strategy is unknown.
Methods and Results— Between February and August 2001, 1058 patients with complex coronary stenoses were enrolled in the SIRIUS trial and randomized to percutaneous coronary revascularization with either a SES or BMS. Clinical outcomes, resource use, and costs were assessed prospectively for all patients over a 1-year follow-up period. Initial hospital costs were increased by $2881 per patient with SESs. Over the 1-year follow-up period, use of SESs led to substantial reductions in the need for repeat revascularization, including repeat percutaneous coronary intervention and bypass surgery. Although follow-up costs were reduced by $2571 per patient with SESs, aggregate 1-year costs remained $309 per patient higher. The incremental cost-effectiveness ratio for SES was $1650 per repeat revascularization event avoided or $27 540 per quality-adjusted year of life gained, values that compare reasonably with other accepted medical interventions. Under updated treatment assumptions regarding available stent lengths and duration of antiplatelet therapy, use of SESs was projected to reduce total 1-year costs compared with BMSs.
Conclusions— Although use of SESs was not cost-saving compared with BMS implantation, for patients undergoing percutaneous coronary intervention of complex coronary stenoses, their use appears to be reasonably cost-effective within the context of the US healthcare system.
Key Words: cost-benefit analysis • restenosis • sirolimus • stents
Related Article:
Circulation 2004 110: 472-474.
This article has been cited by other articles:
 |
|
 |
|
  E.-H. Yao, N. Fukuda, T. Ueno, H. Matsuda, H. Nagase, Y. Matsumoto, H. Sugiyama, and K. Matsumoto A pyrrole-imidazole polyamide targeting transforming growth factor-{beta}1 inhibits restenosis and preserves endothelialization in the injured artery Cardiovasc Res, March 1, 2009; 81(4): 797 - 804. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ryan, W. Linde-Zwirble, L. Engelhart, L. Cooper, and D. J. Cohen Temporal Changes in Coronary Revascularization Procedures, Outcomes, and Costs in the Bare-Metal Stent and Drug-Eluting Stent Eras: Results From the US Medicare Program Circulation, February 24, 2009; 119(7): 952 - 961. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Cohen and M. R. Reynolds Interpreting the results of cost-effectiveness studies. J. Am. Coll. Cardiol., December 16, 2008; 52(25): 2119 - 2126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. G. Firth, L. M. Cooper, and S. Fearn The Appropriate Role Of Cost-Effectiveness In Determining Device Coverage: A Case Study Of Drug-Eluting Stents Health Aff., November 1, 2008; 27(6): 1577 - 1586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Dong, T. Yong, S. Liao, C. K Chan, and S Ramakrishna Long-term viability of coronary artery smooth muscle cells on poly(L-lactide-co-{epsilon}-caprolactone) nanofibrous scaffold indicates its potential for blood vessel tissue engineering J R Soc Interface, September 6, 2008; 5(26): 1109 - 1118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Kirtane and D. J. Cohen When Is Better Not Good Enough?: Insights From the COURAGE Economic Study Circ Cardiovasc Qual Outcomes, September 1, 2008; 1(1): 4 - 6. [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Ladapo, U. Hoffmann, F. Bamberg, J. T. Nagurney, D. M. Cutler, M. C. Weinstein, and G. S. Gazelle Cost-Effectiveness of Coronary MDCT in the Triage of Patients with Acute Chest Pain Am. J. Roentgenol., August 1, 2008; 191(2): 455 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Daemen and P. W. Serruys Drug-Eluting Stent Update 2007: Part II: Unsettled Issues Circulation, August 21, 2007; 116(8): 961 - 968. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rinfret and E. Schampaert Drug-eluting stents Can. Med. Assoc. J., May 22, 2007; 176(11): 1611 - 1612. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Oba Cost-Effectiveness of Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease Mayo Clin. Proc., May 1, 2007; 82(5): 575 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ryan and D. J. Cohen Are Drug-Eluting Stents Cost-Effective?: It Depends on Whom You Ask Circulation, October 17, 2006; 114(16): 1736 - 1744. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Eisenberg Drug-Eluting Stents: The Price Is Not Right Circulation, October 17, 2006; 114(16): 1745 - 1754. [Full Text] [PDF]
|
|
|
|
|
|
K. T. Stroupe, D. A. Morrison, M. A. Hlatky, P. G. Barnett, L. Cao, C. Lyttle, D. M. Hynes, W. G. Henderson, and for the Investigators of Veterans Affairs Cooperat Cost-Effectiveness of Coronary Artery Bypass Grafts Versus Percutaneous Coronary Intervention for Revascularization of High-Risk Patients Circulation, September 19, 2006; 114(12): 1251 - 1257. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Elezi, A. Dibra, U. Folkerts, J. Mehilli, S. Heigl, A. Schomig, and A. Kastrati Cost Analysis From Two Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in High-Risk Patients With Coronary Artery Disease J. Am. Coll. Cardiol., July 18, 2006; 48(2): 262 - 267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bakhai, G. W. Stone, E. Mahoney, T. A. Lavelle, C. Shi, R. H. Berezin, B. J. Lahue, M. A. Clark, M. J. Lacey, M. E. Russell, et al. Cost Effectiveness of Paclitaxel-Eluting Stents for Patients Undergoing Percutaneous Coronary Revascularization: Results From the TAXUS-IV Trial J. Am. Coll. Cardiol., July 18, 2006; 48(2): 253 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Tung, S. Kaul, G. A. Diamond, and P. K. Shah Narrative review: drug-eluting stents for the management of restenosis: a critical appraisal of the evidence. Ann Intern Med, June 20, 2006; 144(12): 913 - 919. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-H. Lee, H.-C. Tan, and Y.-T. Lim Update on Drug-Eluting Stents for Prevention of Restenosis Asian Cardiovasc Thorac Ann, February 1, 2006; 14(1): 75 - 82. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Bagust, A D Grayson, N D Palmer, R A Perry, and T Walley Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study Heart, January 1, 2006; 92(1): 68 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schomig, A. Kastrati, and R. Wessely Prevention of Restenosis by Systemic Drug Therapy: Back to the Future? Circulation, November 1, 2005; 112(18): 2759 - 2761. [Full Text] [PDF]
|
|
|
|
|
|
J. S. Douglas Jr, D. R. Holmes Jr, D. J. Kereiakes, C. L. Grines, E. Block, Z. M.B. Ghazzal, D. C. Morris, H. Liberman, K. Parker, C. Jurkovitz, et al. Coronary Stent Restenosis in Patients Treated With Cilostazol Circulation, November 1, 2005; 112(18): 2826 - 2832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Iakovou, L. Ge, and A. Colombo Contemporary Stent Treatment of Coronary Bifurcations J. Am. Coll. Cardiol., October 18, 2005; 46(8): 1446 - 1455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Valgimigli, G. Percoco, G. Cicchitelli, G. Campo, E. Gardini, L. Pellegrino, P. Malagutti, C. Giretti, and R. Ferrari New and old strategies to afford the liberal use of drug-eluting stents in real-life scenarios Eur. Heart J. Suppl., October 1, 2005; 7(suppl_K): K31 - K35. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zimarino, A. M. Calafiore, and R. De Caterina Complete myocardial revascularization: between myth and reality Eur. Heart J., September 2, 2005; 26(18): 1824 - 1830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hausleiter, A. Kastrati, R. Wessely, A. Dibra, J. Mehilli, T. Schratzenstaller, I. Graf, M. Renke-Gluszko, B. Behnisch, J. Dirschinger, et al. Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating Eur. Heart J., August 1, 2005; 26(15): 1475 - 1481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Pache, A. Dibra, J. Mehilli, J. Dirschinger, A. Schomig, and A. Kastrati Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial Eur. Heart J., July 1, 2005; 26(13): 1262 - 1268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Kereiakes, R. E. Kuntz, L. Mauri, and M. W. Krucoff Surrogates, substudies, and real clinical end points in trials of drug-eluting stents J. Am. Coll. Cardiol., April 19, 2005; 45(8): 1206 - 1212. [Full Text] [PDF]
|
|
|
|
|
|
F. Osman, S. Qaisar, M. Pitt, M. A. Hlatky, D. B. Boothroyd, K. A. Melsop, M. M. Brooks, D. B. Mark, B. Pitt, G. S. Reeder, et al. Letter Regarding Article by Hlatky et al, "Medical Costs and Quality of Life 10 to 12 Years After Randomization to Angioplasty or Bypass Surgery for Multivessel Coronary Artery Disease" * Response Circulation, April 5, 2005; 111(13): e176 - e177. [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, S. Silber, P. Albertsson, F. F. Aviles, P. G. Camici, A. Colombo, C. Hamm, E. Jorgensen, J. Marco, J.-E. Nordrehaug, et al. Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology Eur. Heart J., April 2, 2005; 26(8): 804 - 847. [Full Text] [PDF]
|
|
|
|
|
|
J. M. Brophy The dollars and sense of drug-eluting stents Can. Med. Assoc. J., February 1, 2005; 172(3): 361 - 362. [Full Text] [PDF]
|
|
|
|
|
|
L. Mauri, E. J. Orav, A. J. O'Malley, J. W. Moses, M. B. Leon, D. R. Holmes Jr, P. S. Teirstein, J. Schofer, G. Breithardt, D. E. Cutlip, et al. Relationship of Late Loss in Lumen Diameter to Coronary Restenosis in Sirolimus-Eluting Stents Circulation, January 25, 2005; 111(3): 321 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Carrozza Jr and F. W. Sellke A 69-Year-Old Woman With Left Main Coronary Artery Disease JAMA, November 24, 2004; 292(20): 2506 - 2514. [Full Text] [PDF]
|
|
|
|
|
|
W. S. Weintraub Economics of Sirolimus-Eluting Stents: Drug-Eluting Stents Have Really Arrived Circulation, August 3, 2004; 110(5): 472 - 474. [Full Text] [PDF]
|
|